LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)
Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC
FDA’s Fast Track designation for LB-P8 underlines the urgent need for treatment… อ่านเพิ่ม